BioVie Inc. Files Definitive Proxy Statement

TL;DR

BioVie proxy statement out - vote on directors, auditors, and exec pay.

AI Summary

BioVie Inc. filed its definitive proxy statement on September 27, 2024, for its annual meeting of stockholders. The filing outlines proposals including the election of directors, ratification of the appointment of its independent registered public accounting firm, and advisory approval of executive compensation. The company is seeking shareholder approval for these routine corporate governance matters.

Why It Matters

This filing is crucial for shareholders as it details the proposals they will vote on at the annual meeting, directly impacting the company's governance and executive compensation structure.

Risk Assessment

Risk Level: low — This is a routine annual proxy statement detailing standard corporate governance proposals and does not indicate any immediate financial or operational risks.

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• 0001520138-24-000322 (filing_id) — Accession Number
• 20240927 (date) — Filing Date
• NANOANTIBIOTICS, INC. (company) — Former Company Name

FAQ

Filing Documents

• bivi-def14a.htm (DEF 14A) — 494KB
• image_01.jpg (GRAPHIC) — 3KB
• image_02.jpg (GRAPHIC) — 48KB
• image_03.jpg (GRAPHIC) — 39KB
• image_06.jpg (GRAPHIC) — 49KB
• image_07.jpg (GRAPHIC) — 42KB
• 0001520138-24-000322.txt ( ) — 746KB

From the Filing

DEF 14A 1 bivi-def14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 BIOVIE INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: BIOVIE INC. 680 W Nye Lane, Suite 201 Carson City, NV 89703 (775) 888-3162 NOTICE OF INTENT TO CONVENE IN VIRTUAL MEETING FORMAT THE ANNUAL MEETING OF THE STOCKHOLDERS TO BE HELD ON November 7, 2024 Dear Stockholders of BioVie Inc.: You are invited to participate in the 2024 Annual Meeting (the “Annual Meeting”) of stockholders of BioVie Inc., a Nevada corporation (“BioVie” or the “Company”), to be held on Thursday, November 7, 2024 at 10:00 a.m. Pacific Time. The Board of Directors has determined to convene and conduct the Annual Meeting on Thursday, November 7, 2024 at 10:00 a.m. Pacific Time, in a virtual meeting format at www.virtualshareholdermeeting.com/BIVI2024. Stockholders will NOT be able to attend the Annual Meeting in-person. The accompanying Proxy Statement includes instruction on how to access the virtual Annual Meeting and how to listen, vote, and submit questions from home or any remote location with Internet connectivity. At the Annual Meeting, we will consider and vote upon the following items: 1. To elect six (6) Directors to hold office until the next annual meeting and until their respective successors are elected and qualified (the “Board Election Proposal”); 2. To ratify the appointment of EisnerAmper LLP as BioVie’s independent registered public accounting firm for the 2025 fiscal year (the “Auditor Ratification Proposal”); 3. To conduct a non-binding advisory vote on the compensation of named executive officers (the “Say-on-Pay Proposal”); 4. To approve an amendment and restatement of the 2019 Omnibus Equity Incentive Plan (the “2019 Plan”) to increase the number of shares authorized for issuance up to 1,250,000 (the “2019 Plan Proposal”); and 5. To transact any other business that may properly come before the Annual Meeting or any adjournments or postponements of the Annual Meeting. These items of business are more fully described in the Proxy Statement accompanying this Notice. YOUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR THE NOMINEES AND IN FAVOR OF THE OTHER PROPOSALS OUTLINED IN THE ACCOMPANYING PROXY STATEMENT. The board of directors of BioVie has fixed the close of business on September 30, 2024 as the record date for the Annual Meeting. Only stockholders of record on the record date are entitled to notice of and to vote at the Annual Meeting. Further information regarding voting rights and the matters to be voted upon is presented in the accompanying Proxy Statement. You are cordially invited to participate in the Annual Meeting. Whether or not you expect to participate in the Annual Meeting, please complete, date, sign and return the enclosed proxy or submit your proxy through the internet or by telephone as promptly as possible in order to ensure your representation at the Annual Meeting. If you have requested physical materials to be mailed to you, a return envelope (which is postage prepaid if mailed in the United States) is enclosed for your convenience to use if you choose to submit your proxy by mail. Even if you have voted by proxy, you may still vote online if you attend the virtual Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or othe

View Full Filing

View this DEF 14A filing on SEC EDGAR